Abstract
The epithelial sodium channel (ENaC) plays an essential role in transepithelial sodium reabsorption in the renal connecting tubule and collecting duct. Therefore, controlling ENaC activity is an important regulatory event in electrolyte and extracellular volume homeostasis, and thus in the control of blood pressure. Many independent signaling pathways converge on ENaC, although the most important for its physiological role is the enhancement of channel activity by the steroid hormone aldosterone. In this review, we briefly summarize current knowledge about ENaC regulation and the different chemical compounds available to directly or indirectly modify channel function. In addition, current and possible clinical uses of ENaC and aldosterone antagonists are highlighted.
Keywords: Aldosterone, amiloride, epithelial sodium channel, hypertension, mineralocorticoid receptor.
Current Molecular Pharmacology
Title:ENaC Modulators and Renal Disease
Volume: 6
Author(s): Diego Alvarez de la Rosa, Juan F. Navarro-Gonzalez and Teresa Giraldez
Affiliation:
Keywords: Aldosterone, amiloride, epithelial sodium channel, hypertension, mineralocorticoid receptor.
Abstract: The epithelial sodium channel (ENaC) plays an essential role in transepithelial sodium reabsorption in the renal connecting tubule and collecting duct. Therefore, controlling ENaC activity is an important regulatory event in electrolyte and extracellular volume homeostasis, and thus in the control of blood pressure. Many independent signaling pathways converge on ENaC, although the most important for its physiological role is the enhancement of channel activity by the steroid hormone aldosterone. In this review, we briefly summarize current knowledge about ENaC regulation and the different chemical compounds available to directly or indirectly modify channel function. In addition, current and possible clinical uses of ENaC and aldosterone antagonists are highlighted.
Export Options
About this article
Cite this article as:
Rosa Diego Alvarez de la, Navarro-Gonzalez Juan F. and Giraldez Teresa, ENaC Modulators and Renal Disease, Current Molecular Pharmacology 2013; 6 (1) . https://dx.doi.org/10.2174/1874467211306010005
DOI https://dx.doi.org/10.2174/1874467211306010005 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Triiodothyronine (T3) Effects on Cardiovascular System in Patients with Heart Failure
Recent Patents on Cardiovascular Drug Discovery Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design The Competence of 7,8-Diacetoxy-4-Methylcoumarin and Other Polyphenolic Acetates in Mitigating the Oxidative Stress and their Role in Angiogenesis
Current Topics in Medicinal Chemistry Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Elevation of E-Selectin Concentrations may Correlate with Potential Endothelial Dysfunction in Individuals with Hypopituitarism During Therapy with Growth Hormone
Current Neurovascular Research Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design Acute Coronary Syndromes as Auto-Inflammatory Disorders
Current Pharmaceutical Design Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management
Current Vascular Pharmacology Subject Index To Volume 2
Current Hypertension Reviews Renal Sympathetic Denervation and Renal Physiology
Current Clinical Pharmacology Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?
Current Pharmaceutical Design Subject Index To Volume 3
Current Neurovascular Research Adiponectin as a Regulator of Vascular Redox State: Therapeutic Implications
Recent Patents on Cardiovascular Drug Discovery